Pulmonary Arterial Hypertension (PAH) access in Saudi Arabia: the SFDA named-patient pathway

Creator: Reserve Meds
Published: 2026-05-18

How patients in the Kingdom of Saudi Arabia with PAH legally obtain US-sourced FDA-labelled therapies when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-18 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Saudi Arabia with Pulmonary Arterial Hypertension (PAH) access US-sourced specialty therapies through the SFDA named-patient pathway, a Saudi Food and Drug Authority-administered mechanism that allows a Saudi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the global epidemiology of PAH, the treatment options that typically travel through the cross-border route, real-world timelines, and the cost band in SAR terms.

Reserved for you.

Epidemiology and clinical context of Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension (PAH) is defined haemodynamically by a mean pulmonary arterial pressure above 20 mmHg with pulmonary vascular resistance at least 2 Wood units and a normal pulmonary artery wedge pressure. The condition is rare, with prevalence estimates of 15 to 50 per million adults. Subtypes include idiopathic, heritable, drug-and-toxin-induced, connective-tissue-disease-associated, congenital-heart-disease-associated, and other categories. Modern combination therapy targeting endothelin, nitric-oxide, and prostacyclin pathways has substantially improved survival.

Global prevalence is in the range of approximately 15-50 per million adults (1.5-5 per 100,000). ICD-10 classifies the condition under I27.0. The clinical picture in Saudi Arabia reflects the same biological substrate, though referral patterns, age at diagnosis, and access to specialised diagnostic centres vary by region.

Why Saudi families pursue the named-patient route for PAH

the Kingdom of Saudi Arabia operates a structured pharmaceutical regulatory environment. Modern PAH therapy is regulated through SFDA channels, and a Saudi family seeking cross-border supply is rarely asking for a treatment that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.

Four converging patterns drive these cases. First, indication lag - newer FDA-approved indications and dosing expansions for PAH therapies reach local registration 12 to 36 months after the US label. Second, presentation gaps - the exact strength, weight-banded dose, pediatric vial size, or device format the prescriber requires may not be stocked at the local agent even when the medicine is registered. Third, payer denial - Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, and the CCHI-regulated employer plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register; cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply - when a US-stable patient relocates to Saudi Arabia or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.

In each pattern, the SFDA named-patient pathway is the mechanism that connects a Saudi-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient.

The SFDA named-patient pathway in detail

The pathway for a Saudi-licensed physician to obtain a medicine that is not registered or not stocked locally is the SFDA Special Access Programme administered through the Ghad platform, which allows a Saudi-licensed physician at a registered healthcare facility to import an unregistered medicine for a specific named patient where the medicine is approved by a recognised reference authority and no clinically equivalent locally registered option is suitable. The framework allows registered healthcare facilities to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable.

For PAH, the clinical justification typically frames the case around WHO functional class II-IV PAH; combination oral therapy; parenteral prostacyclin escalation. A complete application includes a clinical justification letter from the treating physician (diagnosis with confirmatory genetic or biomarker testing where relevant, severity scores, prior therapies and their outcomes, why this specific drug, why the locally stocked option is not suitable), the treating physician's Saudi medical license verification through the Saudi Commission for Health Specialties (SCFHS) and the SFDA, an anonymised patient identifier where the SFDA submission allows, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity requested, intended treatment duration), the destination dispensing facility name, license number, and pharmacy in charge, and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy.

Approval timelines for routine cases are typically 7 to 21 business days. Complex cases (rare indication, larger quantities, first import of a given pediatric or weight-banded format, ultra-cold cell and gene therapies) can extend to 6 to 8 weeks. SFDA retains discretion on timing, and we do not promise specific durations.

Treatment options that travel through the SFDA route for PAH

Modern disease-modifying or symptomatic therapy for PAH spans a small set of brand-name products, most of which originate from US-headquartered or US-licensed manufacturers and reach the FDA-approved label before equivalent registration in Saudi Arabia. The list below captures the products most frequently requested by Saudi specialists through the named-patient route. Each links to its drug-specific access page on Reserve Meds with regulatory, logistics, and cost detail.

Opsumit (macitentan) is an endothelin-receptor antagonist used in PAH combination regimens.
Adempas (riociguat) is a soluble guanylate cyclase stimulator approved for PAH and CTEPH.
Uptravi (selexipag) is an oral prostacyclin-receptor agonist for PAH.
Winrevair (sotatercept) is an activin-signalling inhibitor approved in 2024 as add-on therapy for PAH.

Choice of therapy depends on the patient's full phenotype, genotype where relevant, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Real cost band for PAH in Saudi Arabia

Modern PAH therapies span a wide cost spectrum, from small-molecule oral therapies in the four- to five-figure annual US-WAC range to one-time gene therapies above USD one million per administration. The firm quote we send back includes the exact drug-cost line for the prescribed regimen against current manufacturer list pricing (Roche, Novartis, Sanofi, Pfizer, BioMarin, Sarepta, Vertex, Bluebird Bio, BioMarin, CSL, Bayer, Lilly, or others as applicable). The SAR conversion is calculated at the prevailing rate on the day of quote issue.

International logistics for shipment to Saudi Arabia typically runs USD 400 to USD 1,500 depending on destination city, urgency, and presentation: cold-chain biologics and gene therapies carry the higher end of the range; ambient oral solids the lower. the Kingdom of Saudi Arabia customs and SFDA permit fees are nominal relative to drug cost. Reserve Meds' concierge fee is itemised separately on every firm quote.

On the insurance side, Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, and the CCHI-regulated employer plans each assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We do not promise coverage from any insurer. US manufacturer copay cards and patient assistance programs do not extend internationally; cross-border patients pay cash or rely on local payer coverage.

Where PAH therapies get dispensed in Saudi Arabia

A small group of Saudi institutions handle named-patient imports for rare and specialty conditions as established workflow, with in-house import pharmacy infrastructure and physicians experienced with the application set. Tertiary and major private hospitals that meet this profile include King Faisal Specialist Hospital and Research Centre (KFSH&RC), King Abdulaziz Medical City (KAMC), King Saud University Medical City in Riyadh, King Abdullah Medical City in Makkah, and Dr. Sulaiman Al Habib Medical Group. Each maintains pharmacy infrastructure appropriate to the relevant presentation (2 to 8 degrees Celsius cold-chain for biologics, ultra-cold or specialised handling for cell and gene therapies, ambient storage for oral therapies).

For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a specialty importer that holds a pharmaceutical establishment license and files the SFDA application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's outpatient or specialty pharmacy under chain-of-custody documentation. For one-time cell and gene therapies in particular, the dispensing facility must demonstrate qualified storage, documented temperature monitoring, infusion or apheresis capability where applicable, and a chain-of-custody record that meets the manufacturer's risk-evaluation-and-mitigation expectations.

Common questions about PAH access in Saudi Arabia

Is PAH treated through the SFDA named-patient pathway in Saudi Arabia?

Yes. When the prescribing Saudi specialist documents that a specific PAH therapy is not registered or not stocked in Saudi Arabia, the SFDA pathway provides the regulatory mechanism to import the FDA-approved product for a specific named patient. the SFDA Special Access Programme administered through the Ghad platform.

How long does SFDA approval typically take?

Routine cases run 7 to 21 business days from a complete filing. Complex cases (rare indication, first import of a pediatric or weight-banded format, larger quantities) can extend to 6 to 8 weeks. SFDA retains discretion on timing; Reserve Meds does not promise specific durations.

What does PAH treatment cost in Saudi Arabia?

The drug-cost line tracks US wholesale acquisition cost (WAC) for the prescribed product; the firm quote we send back includes the exact figure against current manufacturer list pricing. International logistics into Saudi Arabia typically runs USD 400 to USD 1,500 depending on destination city, urgency, and cold-chain requirements. SFDA permit fees are nominal relative to drug cost. The Reserve Meds concierge fee is itemised separately on every firm quote.

Will Bupa Arabia cover this?

Each insurer assesses named-patient imports case by case. Some Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, and the CCHI-regulated employer plans reimburse fully when the medicine is on the formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that lets your insurer assess the case; the claim sits with you or your hospital.

Which Saudi hospitals dispense Opsumit and similar specialty therapies?

Tertiary and major private hospitals that maintain in-house import pharmacy infrastructure include King Faisal Specialist Hospital and Research Centre (KFSH&RC), King Abdulaziz Medical City (KAMC), King Saud University Medical City in Riyadh, King Abdullah Medical City in Makkah, and Dr. Sulaiman Al Habib Medical Group. Each operates pharmacy storage appropriate to the relevant presentation (2 to 8 degrees Celsius cold-chain for biologics, ultra-cold for select cell and gene therapies, ambient storage for oral therapies).

Where Reserve Meds fits in PAH cases in Saudi Arabia

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace SFDA, and we do not replace your dispensing pharmacy. For PAH cases specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it, ultra-cold handling for relevant cell and gene therapies) into Saudi Arabia, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies.

A typical PAH case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing or administration plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the SFDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks run in parallel, not in series; that is the operational difference between a 3-week and a 9-week case.

Next step

If your Saudi physician is treating PAH and is weighing the cross-border route for a specific FDA-approved therapy, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your case WhatsApp